Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this phase 3b study is to determine the safety and efficacy of
moxidectin administration twice a year, compared to once a year, in maintaining undetectable
levels in skin of O. volvulus microfilaria in skin, the parasite that causes river blindness.
Secondary purposes are to determine the effectiveness of moxidectin compared to ivermectin
once or twice a year in maintaining undetectable levels, or reducing levels, of skin
microfilaria.
Phase:
Phase 3
Details
Lead Sponsor:
Medicines Development for Global Health Medicines Development Limited